In response to the financial hit many people are taking due to the coronavirus pandemic, Eli Lilly (LLY) is lowering the cost for most of its insulin products to $35 a month for anyone with commercial insurance or those who lack health coverage altogether.
The move, which will also reset copay cards to the same monthly $35 level, comes amid ongoing angst over the cost of the diabetes treatment. Insulin, in fact, has been something of a poster child for the national debate over prescription drugs costs.
About the Author Reprints
